LakeShore Biopharma Co Long Term Debt

LakeShore Biopharma Co's long-term debt stands at $24M as of March 2025. That compares with $100M in the prior-year period — down 76.7% year over year. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

LakeShore Biopharma Co reported $24M in long-term debt versus $100M a year earlier — a 76.7% year-over-year decrease. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.

That compares with $100M in the prior-year period — down 76.7% year over year. Sustained growth in long-term debt can support a stronger franchise, while sharp declines may reflect divestitures, weaker demand, or accounting changes. Always read YoY moves with the footnotes of recent filings in mind.

The history chart shows how LakeShore Biopharma Co's long-term debt evolved across reporting periods, while the comparison chart places LSB next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.